Metabolic & Body Composition
Cagrilintide
Long-acting analog of amylin in advanced clinical development. In combination with semaglutide (CagriSema), it demonstrates up to 25% weight loss in clinical trials.
Also known as: AM833
Specifications
| Research area | Metabolic & Body Composition | ||
|---|---|---|---|
| Half-life | ~7–8 days | ||
| Molecular weight | 3416.0 Da | ||
Research areas
Weight lossAppetiteSatietyMetabolism
- Mechanism of action
- Amylin receptor agonist (CALCR/RAMP) that reduces food intake, slows gastric emptying, and promotes satiety. It complements the action of GLP-1 agonists by targeting distinct satiety pathways.
- Reported research ranges
- 0.3–2.4 mg subcutaneously per week (gradual escalation).
- Reported adverse effects
- Nausea, vomiting, injection site reactions. Similar to GLP-1.
- Storage and handling
- Refrigerate at 2–8 °C.
This material is published for scientific and educational reference. It is not medical advice, not a treatment recommendation, and not an offer to sell. Compounds discussed are for research and laboratory use only.
← All compounds